PET-DECT for Staging and Imaged Based Radiotherapy Planning in Lung Cancer
The overall goal of this project is to investigate the diagnostic performance of integrated F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) and Dual Energy CT (DECT) imaging in determining the thoracic nodal status of small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC), and its impact on target volume delineation for image guided radiation therapy (IGRT) planning.
Checked against the public recordLast updated Jun 21, 2018 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- Medical University of South Carolina
- Interventions being studied
- Not specified
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: To be eligible for the study: (All answers must be "YES" for subject to be eligible.) 1. Subject must have a suspected SCLC or NSCLC. 2. Subject must be 18-90 years of age. 3. Subject must have been referred for a clinically indicated PET-CT. 4. Subject must provide written informed consent prior to any study-related procedures being performed. 5. Subject must be willing to comply with all clinical study procedures. Exclusion Criteria: The presence of the following excludes subjects from the study: (All answers must be "NO" for subject to be eligible.) 1. Subject is a pregnant or nursing female. Exclude the possibility of pregnancy: * By testing (serum or urine βHCG) within 24 hours before contrast agent administration, or * By surgical sterilization, or * Post-menopausal, with minimum one (1) year history without menses. 2. Subject has impaired renal function (eGFR\<30 mL/min). 3. Subject has an acute psychiatric disorder or is cognitively impaired. 4. Subject is using or is dependent on substances of abuse. 5. Subject is unwilling to comply with the requirements of the protocol. 6. Subject has an allergy against iodinated contrast agents and cannot be premedicated. 7. Subject is in acute unstable condition.
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Medical University of South CarolinaCharleston, South Carolina
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 21, 2018. Always confirm current availability with the study team.